NASDAQ:SRPT

Sarepta Therapeutics (SRPT) Stock Forecast, Price & News

$119.93

+0.38 (+0.32%)

(As of 09/22/2023 ET)

Compare

Today's Range: $119.65
▼
$121.82
50-Day Range: $102.50
▼
$122.86
52-Week Range: $100.15
▼
$159.89

Volume: 553,449 shs
Average Volume: 756,488 shs
Market Capitalization: $10.55 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $173.70

Sarepta Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.93 Rating Score
Upside/Downside: 44.8% Upside
$173.70 Price Target
Short Interest: Bearish
5.24% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.65
Upright™ Environmental Score
News Sentiment: 1.03
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$4.79 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($9.21) to ($1.37) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

289th out of 963 stocks

Pharmaceutical Preparations Industry

120th out of 458 stocks

3.5

Analyst's Opinion

Consensus Rating
Sarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $173.70, Sarepta Therapeutics has a forecasted upside of 44.8% from its current price of $119.93.
Amount of Analyst Coverage
Sarepta Therapeutics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.24% of the outstanding shares of Sarepta Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Sarepta Therapeutics has a short interest ratio ("days to cover") of 4.3.
Change versus previous month
Short interest in Sarepta Therapeutics has recently increased by 4.06%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Sarepta Therapeutics does not currently pay a dividend.
Dividend Growth
Sarepta Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Sarepta Therapeutics is -1.65.

2.8

News and Social Media Coverage

News Sentiment
Sarepta Therapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Sarepta Therapeutics this week, compared to 7 articles on an average week.
Search Interest
23 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 5% compared to the previous 30 days.
MarketBeat Follows
Only 13 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sarepta Therapeutics insiders have bought 199.45% more of their company's stock than they have sold. Specifically, they have bought $4,793,533.00 in company stock and sold $1,600,800.00 in company stock.
Percentage Held by Insiders
Only 7.40% of the stock of Sarepta Therapeutics is held by insiders.
Percentage Held by Institutions
91.82% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sarepta Therapeutics are expected to grow in the coming year, from ($9.21) to ($1.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sarepta Therapeutics is -11.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sarepta Therapeutics is -11.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sarepta Therapeutics has a P/B Ratio of 27.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

SRPT Price History

30 days | 90 days | 365 days | Advanced Chart

SRPT Stock News Headlines

September 8, 2023 | insidertrades.com

Insiders Are Buying These 2 Stocks (SRPT)

September 23, 2023 | money.usnews.com

Sarepta Therapeutics Inc

September 24, 2023 | Legacy Research (Ad)

The Real Reason They Murdered JFK?

Some people believe JFK was murdered because of his executive order 11110 that would have reduced the power of the Federal Reserve. Regardless if that’s true or not… The Fed is now involved in a new controversy that could have drastic consequences for the US dollar.

September 16, 2023 | fool.com

Sarepta Therapeutics (NASDAQ: SRPT)

September 15, 2023 | barrons.com

S&P 500 Futures Climb in Premarket Trading; Sarepta Therapeutics, Unity Software Lead

September 14, 2023 | finance.yahoo.com

2 Top Growth Stocks to Buy With $500

September 14, 2023 | americanbankingnews.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of "Moderate Buy" from Analysts

September 13, 2023 | seekingalpha.com

Sarepta: Broad Label Expansion Possible With Q4 2023 Catalyst

September 24, 2023 | Legacy Research (Ad)

The Real Reason They Murdered JFK?

September 7, 2023 | finance.yahoo.com

Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year

September 5, 2023 | finance.yahoo.com

Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

September 1, 2023 | finance.yahoo.com

Sarepta Therapeutics (SRPT) Up 12.7% Since Last Earnings Report: Can It Continue?

August 30, 2023 | markets.businessinsider.com

Quest Diagnostics Says FDA Grants Breakthrough Designation For Adeno-associated Virus Test

August 30, 2023 | finance.yahoo.com

Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test

August 30, 2023 | finance.yahoo.com

FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%

August 27, 2023 | finance.yahoo.com

SRPT Aug 2023 102.000 call

August 23, 2023 | finance.yahoo.com

Is Sarepta Therapeutics Stock a Top Growth Vehicle?

August 16, 2023 | seekingalpha.com

Sarepta Eyes Broadened Label For ELEVIDYS Amid Progress (Rating Upgrade)

August 14, 2023 | benzinga.com

Massive Insider Trade At Sarepta Therapeutics

August 14, 2023 | msn.com

Take a Look at Sarepta’s (NASDAQ:SRPT) Latest Insider Trade

August 13, 2023 | finance.yahoo.com

Sarepta Therapeutics' Michael Chambers Acquires 19% More Stock

August 4, 2023 | finance.yahoo.com

FDA-approved gene therapy invented at Nationwide Children's carries a $3.2M price tag. Here's why.

August 3, 2023 | finance.yahoo.com

Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss

August 3, 2023 | markets.businessinsider.com

Sarepta Therapeutics (SRPT) Gets a Buy from Mizuho Securities

August 2, 2023 | finance.yahoo.com

Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments

August 2, 2023 | markets.businessinsider.com

Sarepta Therapeutics Q2 Loss Decreases, beats estimates

August 2, 2023 | finance.yahoo.com

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates

See More Headlines

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Company Calendar

Last Earnings: 8/02/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SRPT
Previous Symbol: NASDAQ:AVII
CUSIP: N/A
CIK: 873303
Web: www.sareptatherapeutics.com
Phone: (617) 274-4000
Fax: 425-354-5038
Employees: 1,162
Year Founded: 1980

Price Target and Rating

Average Stock Price Forecast: $173.70
High Stock Price Forecast: $223.00
Low Stock Price Forecast: $125.00
Forecasted Upside/Downside: +44.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.93
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($10.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-703,490,000.00
Net Margins: -90.46%
Pretax Margin: -88.20%
Return on Equity: -91.22%
Return on Assets: -16.60%

Debt

Debt-to-Equity Ratio: 1.67
Current Ratio: 4.96
Quick Ratio: 4.50

Sales & Book Value

Annual Sales: $933.01 million
Price / Sales: 11.31
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.39 per share
Price / Book: 27.32

Miscellaneous

Outstanding Shares: 88,000,000
Free Float: 81,488,000
Market Cap: $10.55 billion
Optionable: Optionable
Beta: 0.94

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Douglas S. Ingram Esq. (Age 60)
Pres, CEO & Director
Comp: $1.62M

Mr. Ian Michael Estepan (Age 47)
Exec. VP & CFO
Comp: $917.53k

Dr. Louise R. Rodino-Klapac Ph.D. (Age 45)
Exec. VP, Chief Scientific Officer and Head of R&D
Comp: $1.04M

Mr. Ryan E. Brown J.D. (Age 45)
Exec. VP, Gen. Counsel & Corp. Sec.
Comp: $823.36k

Mr. Bilal Arif (Age 51)
Exec. VP & Chief Technical Operations Officer

Mary Jenkins
Sr. Mang. of Investor Relations

Ms. Alison Nasisi
Exec. VP & Chief People Officer

Dr. Diane L. Berry Ph.D.
Exec. VP and Chief of Global Policy & Advocacy Officer

Mr. Dallan Murray
Exec. VP & Chief Customer Officer

Mr. Will Tilton
Sr. VP, Head of Strategy & Chief of Staff

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SRPT Stock - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SRPT shares.
View SRPT analyst ratings or view top-rated stocks.
What is Sarepta Therapeutics' stock price forecast for 2023?: 15 equities research analysts have issued 12-month target prices for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $125.00 to $223.00. On average, they anticipate the company's share price to reach $173.70 in the next twelve months. This suggests a possible upside of 44.8% from the stock's current price.
View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts.
How have SRPT shares performed in 2023?: Sarepta Therapeutics' stock was trading at $129.58 at the beginning of 2023. Since then, SRPT stock has decreased by 7.4% and is now trading at $119.93.
View the best growth stocks for 2023 here.
When is Sarepta Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our SRPT earnings forecast.
How were Sarepta Therapeutics' earnings last quarter?: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($1.89) by $1.62. The biotechnology company had revenue of $261.20 million for the quarter, compared to analysts' expectations of $255.99 million. Sarepta Therapeutics had a negative net margin of 90.46% and a negative trailing twelve-month return on equity of 91.22%. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.65) EPS.
What ETFs hold Sarepta Therapeutics' stock?: ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Morningstar US Small Growth (MSGR), Global X Genomics & Biotechnology ETF (GNOM), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and American Century Mid Cap Growth Impact (MID).
What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?: 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Sarepta Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?: Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
Who are Sarepta Therapeutics' major shareholders?: Sarepta Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.25%), Bank of New York Mellon Corp (2.61%), State Street Corp (2.17%), Geode Capital Management LLC (1.58%), Casdin Capital LLC (1.15%) and Goldman Sachs Group Inc. (1.10%). Insiders that own company stock include Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers and Stephen Mayo.
View institutional ownership trends.
How do I buy shares of Sarepta Therapeutics?: Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sarepta Therapeutics' stock price today?: One share of SRPT stock can currently be purchased for approximately $119.93.
How much money does Sarepta Therapeutics make?: Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $10.55 billion and generates $933.01 million in revenue each year. The biotechnology company earns $-703,490,000.00 in net income (profit) each year or ($10.31) on an earnings per share basis.
How many employees does Sarepta Therapeutics have?: The company employs 1,162 workers across the globe.
Does Sarepta Therapeutics have any subsidiaries?: The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.
Read More
How can I contact Sarepta Therapeutics?: Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial